Immunotherapy of melanoma

por Haanen, John B.A.G.
Publicado 2013

Questions asked in the everyday practice: immune checkpoint inhibitors

por Haanen, John B A G
Publicado 2018

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers

por Tas, Liselotte, Jedema, Inge, Haanen, John B.A.G.
Publicado 2023

Adoptive cellular therapies: the current landscape

por Rohaan, Maartje W., Wilgenhof, Sofie, Haanen, John B. A. G.
Publicado 2018

Naked Plasmid DNA Formulation: Effect of Different Disaccharides on Stability after Lyophilisation

por Quaak, Susanne G. L., Haanen, John B. A. G., Beijnen, Jos H., Nuijen, Bastiaan
Publicado 2010

Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events

por Hoefsmit, Esmée P., Rozeman, Elisa A., Haanen, John B. A. G., Blank, Christian U.
Publicado 2019

Selective Expansion of Cross-Reactive Cd8(+) Memory T Cells by Viral Variants

por Haanen, John B.A.G., Wolkers, Monika C., Kruisbeek, Ada M., Schumacher, Ton N.M.
Publicado 1999

Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option

por Rohaan, Maartje W., van den Berg, Joost H., Kvistborg, Pia, Haanen, John B. A. G.
Publicado 2018

Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy

por Borm, Frank J., Smit, Jasper, Oprea-Lager, Daniela E., Wondergem, Maurits, Haanen, John B. A. G., Smit, Egbert F., de Langen, Adrianus J.
Publicado 2021

Fixed Dosing of Monoclonal Antibodies in Oncology

por Hendrikx, Jeroen J.M.A., Haanen, John B.A.G., Voest, Emile E., Schellens, Jan H.M., Huitema, Alwin D.R., Beijnen, Jos H.
Publicado 2017

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

por Retèl, Valesca P., Steuten, Lotte M. G., Geukes Foppen, Marnix H., Mewes, Janne C., Lindenberg, Melanie A., Haanen, John B. A. G., van Harten, Wim H.
Publicado 2018

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

por Rohaan, Maartje W., Stahlie, Emma H. A., Franke, Viola, Zijlker, Lisanne P., Wilgenhof, Sofie, van der Noort, Vincent, van Akkooi, Alexander C. J., Haanen, John B. A. G.
Publicado 2022

Identification of patient-specific CD4(+) and CD8(+) T cell neoantigens through HLA-unbiased genetic screens

por Cattaneo, Chiara M., Battaglia, Thomas, Urbanus, Jos, Moravec, Ziva, Voogd, Rhianne, de Groot, Rosa, Hartemink, Koen J., Haanen, John B. A. G., Voest, Emile E., Schumacher, Ton N., Scheper, Wouter
Publicado 2023

[(18)F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma

por Vos, Joris L., Zuur, Charlotte L., Smit, Laura A., de Boer, Jan Paul, Al-Mamgani, Abrahim, van den Brekel, Michiel W. M., Haanen, John B. A. G., Vogel, Wouter V.
Publicado 2021

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characterist...

por van der Hiel, Bernies, Haanen, John B.A.G., Stokkel, Marcel P.M., Peeper, Daniel S., Jimenez, Connie R., Beijnen, Jos H., van de Wiel, Bart A., Boellaard, Ronald, van den Eertwegh, Alfons J.M.
Publicado 2017

T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production

por van Asten, Saskia D., de Groot, Rosa, van Loenen, Marleen M., Castenmiller, Suzanne M., de Jong, Jeroen, Monkhorst, Kim, Haanen, John B.A.G., Amsen, Derk, Bex, Axel, Spaapen, Robbert M., Wolkers, Monika C.
Publicado 2021

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

por Meerveld-Eggink, Aafke, Graafland, Niels, Wilgenhof, Sofie, Van Thienen, Johannes V., Lalezari, Ferry, Grant, Michael, Szabados, Bernadett, Abu-Ghanem, Yasmin, Kuusk, Teele, Boleti, Ekaterini, Blank, Christian U., Haanen, John B.A.G., Powles, Thomas, Bex, Axel
Publicado 2022

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8(+) T-cell and Activated Treg Compartment

por van der Leun, Anne M., Traets, Joleen J.H., Vos, Joris L., Elbers, Joris B.W., Patiwael, Sanne, Qiao, Xiaohang, Machuca-Ostos, Mercedes, Thommen, Daniela S., Haanen, John B.A.G., Schumacher, Ton N.M., Zuur, Charlotte L.
Publicado 2023

Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management

por Geukes Foppen, Marnix H, Rozeman, Elisa A, van Wilpe, Sandra, Postma, Cindy, Snaebjornsson, Petur, van Thienen, Johannes V, van Leerdam, Monique E, van den Heuvel, Michel, Blank, Christian U, van Dieren, Jolanda, Haanen, John B A G
Publicado 2018

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

por Verdegaal, Els M. E., Visser, Marten, Ramwadhdoebé, Tamara H., van der Minne, Caroline E., van Steijn, Jeanne A. Q. M. J., Kapiteijn, Ellen, Haanen, John B. A. G., van der Burg, Sjoerd H., Nortier, Johan W. R., Osanto, Susanne
Publicado 2011